The regulatory filings for Bmab 1200 in certain markets are currently under review. Credit: Corona Borealis Studio/Shutterstock.

Biocon Biologics has reached a settlement and licence agreement with Janssen Biotech, Janssen Sciences Ireland and Johnson & Johnson (collectively called Janssen) for the commercialisation of Bmab 1200 (bUstekinumab), a proposed biosimilar to Stelara (Ustekinumab).

Biocon plans to commercialise the product in key markets such as Europe, the United Kingdom, Canada and Japan on receipt of regulatory approvals.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The agreement resolves patent disputes between the parties and enables market entry for Biocon Biologics’ product in these regions.

The regulatory filings for Bmab 1200 are currently under review.

The development follows the company’s previous announcement of a settlement agreement in the US, which permits the launch of Bmab 1200 no later than 22 February 2025, pending approval from the US Food and Drug Administration (FDA).

See Also:

The FDA has accepted the company’s biologics licence application for Bmab 1200 under the 351(k) pathway.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Stelara is a monoclonal antibody indicated to treat various immune-mediated ailments by targeting interleukin IL-12/23.

It is approved for conditions such as psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

The reference brand, Stelara, reported global sales of $10.85bn in 2023.

Biocon Biologics CEO and managing director Shreehas Tambe stated: “This settlement agreement is testament to our proven track record of science and innovation and is another key milestone in our journey to bring our biosimilar Bmab 1200 (bUstekinumab) to global markets.

“Bmab 1200 will significantly strengthen our immunology franchise, enabling us to offer an affordable and effective treatment option for patients impacted by autoimmune diseases.”

In May 2024, Biocon entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea.